SCHEMBL257415

SCHEMBL257415

CC1=CCSC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10296433 0.71
SCHEMBL10296431 0.71
SCHEMBL7533897 0.63
SCHEMBL17220470 0.62
SCHEMBL8758 0.58
SCHEMBL895220 0.58
SCHEMBL12179431 0.58
SCHEMBL619486 0.57
SCHEMBL7214362 0.57
SCHEMBL7192234 0.57

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1799162-A Lithium secondary battery MITSUBISHI CHEM CORP (JP) 2006-07-05 CN claimed
WO-2023147312-A1 AMPK AGONISTS AND METHODS OF USE THEREOF EVVIA THERAPEUTICS, INC. (US) 2023-08-03 WO disclosed
US-20230002393-A1 CDK KINASE INHIBITOR BEIJING BENICALL BIOTECH CO LTD (CN) 2023-01-05 US disclosed
WO-2022179469-A1 THIENOPYRIMIDINEDIONE COMPOUNDS AND APPLICATION THEREOF 南京明德新药研发有限公司 2022-09-01 WO disclosed
US-20220145339-A1 METHOD FOR PREPARATION OF PRIMARY AMINE COMPOUNDS MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) 2022-05-12 US disclosed
EP-3988551-A1 CDK KINASE INHIBITOR Beijing Benicall Biotech Co., Ltd. (CN) 2022-04-27 EP disclosed
WO-2020253458-A1 CDK KINASE INHIBITOR 北京睿熙生物科技有限公司 2020-12-24 WO disclosed
WO-2020120420-A1 METHOD FOR PREPARATION OF PRIMARY AMINE COMPOUNDS MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2020-06-18 WO disclosed
US-10000476-B2 Pyridone derivative, pharmaceutical containing the same and methods of use thereof KAKEN PHARMACEUTICAL CO., LTD. (JP) 2018-06-19 US disclosed
EP-2789607-B1 PYRIDONE DERIVATIVE AND MEDICINE CONTAINING SAME KAKEN PHARMA CO LTD (JP) 2018-02-07 EP disclosed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed
US-20070213326-A1 SUBSTITUTED INDOLE COMPOUNDS AND THEIR USE AS 5-HT6 RECEPTOR MODULATORS LABORATORIOS DEL DR. ESTEVE S.A. (ES) 2007-09-13 US disclosed
US-20070213326-A1 SUBSTITUTED INDOLE COMPOUNDS AND THEIR USE AS 5-HT6 RECEPTOR MODULATORS LABORATORIOS DEL DR. ESTEVE S.A. (ES) 2007-09-13 US disclosed
WO-2007069773-A1 A PHARMACEUTICAL COMPOSITION COMPRISING AN AMIDE DERIVATIVE SHIONOGI & CO., LTD. (JP) 2007-06-21 WO disclosed
WO-2007060028-A1 NAPTHYRIDINE COMPOUNDS AS ROCK INHIBITORS GPC BIOTECH AG (DE) 2007-05-31 WO disclosed
EP-1757607-A1 N5-substituted benzo¬2,3|azepino¬4,5-b|indol-6-ones for treating tropical diseases Molisa GmbH (DE) 2007-02-28 EP disclosed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 WO disclosed
US-20040242928-A1 Tumor necrosis factor converting enzyme inhibitor; antiarthritic agents; lupus; Crohn's disease; multiple sclerosis; antidiabetic agents; infections;; asthma; skin disorders; anemia STUDOR S.A. (LU) 2004-12-02 US disclosed
EP-1431285-A1 REVERSE HYDROXAMIC ACID DERIVATIVES Kaken Pharmaceutical Co., Ltd. (JP) 2004-06-23 EP disclosed